About Image


      Bone Biologics is committed to the principle of equal employment opportunity. Applicants for employment and employees are reviewed on their individual qualifications for a position. Bone Biologics does not discriminate in recruitment, hiring, training, promotion or any other employment practice.

      If you are interested in being part of our team, please send a resume and cover letter to:



      Leadership Image


          The Bone Biologics leadership team consists of some of the top leaders and innovators of orthobiologics in regenerative medicine. Not only does our leadership provide strategic oversight of the Company, they contribute to the collective advancement of the industry. This leadership is instrumental in fulfilling our mission to improve clinical outcomes and reduce health care delivery costs associated with lumbar spinal fusion.


          Products Image


              While Bone Biologics has chosen to focus its initial product development efforts in spinal fusion, we believe that this regenerative medicine technology has potential in the broader fields of bone regeneration and repair including osteoporosis, chondrocytes and applications using mesenchymal stem cells.


              Investor Relations

              Investor Relations Image

                  Investor Relations

                  Bone Biologics was founded in 2004 by Dr. Chia Soo, MD/Vice-Chair and Professor, UCLA Hospital Dept of Orthopedic Surgery; Dr. Kang Ting DMD, DMSc/Professor, UCLA Dental School; and Dr. Benjamin Wu, DDS, PhD/Chair and Professor, UCLA Dept of Bioengineering.The Company was acquired in 2006 by MTF, the major shareholder and primary funder since the acquisition.

                  Headquartered in Burlington, Massachusetts, USA, Bone Biologics became a public company in September 2014 and is focused on bone repair and regeneration applications. The company is committed to exploring additional applications of the NELL-1 technology to enhance bone regeneration and repair in areas where the current options provide suboptimal patient outcomes.


                  Contact Image


                      General Inquiries:
                      Chris Martin
                      412.749.9299 x2

                      Investor Inquiries:
                      Mark Collinson

                      Media Inquiries:
                      Tracy Williams
                      310.824.9000 x22

                      For information regarding our company and/or products, please complete the form below.

                      Your Name (required)



                      Email (required)


                      Preferred Means of Reply

                      Your Message

                      Scratch Pad
                      Parent : about 4